Company’s Research Initiative Recognized as Novel, Innovative Approach to Deliver More Personalized Dialysis Treatment
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that a project featuring the Tablo™ Hemodialysis System has been selected as a winner of the KidneyX Redesign Dialysis Competition. Outset’s winning concept seeks to couple data from Tablo’s unique set of sensors and automation capabilities with physiologic data from the patient to deliver personalized dialysis treatments, ultimately improving outcomes for patients.
The KidneyX Redesign Dialysis Competition is a partnership between the U.S. Department of Health and Human Services and the American Society of Nephrology to support innovative strategies for tackling kidney disease, a space that has been historically underfunded despite a growing patient population and poor patient outcomes, including high mortality and low quality of life. These sub-optimal outcomes are due in part to dialysis treatment decisions driven by incomplete, imprecise physiologic measurements and a one-size-fits-all approach to treatment planning. Tablo has a proprietary suite of sensors and data sets that can allow it to merge data from the machine and the patient in order to automatically adjust treatment parameters and customize therapy to an individual patient’s needs, all without interrupting clinic workflow.
Read More: https://www.businesswire.com/news/home/20190429005751/en/Outset-Medical-Announced-KidneyX-Award-Winner-U.S./?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT
Outset Medical Announced a KidneyX Award Winner by U.S. Department of Health and Human Services and the American Society of Nephrology
Via: The Times-News
The Centers for Disease Control and Prevention reports that nearly 800,000 people in the United States have suffered strokes. Stroke Awareness Month, which occurs in May, is quickly approaching, which makes this a good time to discuss the medical advances in this area. Thankfully, the medical field is rapidly advancing, and new techniques and procedures are created every year. Transcarotid artery revascularization (TCAR) is one such procedure that can change the lives of patients at risk for stroke.
Shares of Silk Road Medical (SILK) popped more than 80% on Thursday with an initial public offering that drew heavy interest from investors. The Silk Road Medical IPO raised $120 million.
SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk Road Medical. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Silk Road Medical’s common stock is expected to begin trading on The Nasdaq Global Market on April 4, 2019, under the ticker symbol “SILK”. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silk Road Medical, are expected to be approximately $120 million. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders if the underwriters exercise their option to purchase additional shares. The offering is expected to close on April 8, 2019, subject to the satisfaction of customary closing conditions.
Medical device company Silk Road Medical (SILK) priced its initial public offering at 20 a share, at the high end of its recently raised expected range. The Silk Road IPO garnered lots of attention from investors, with one IPO research firm giving the company its highest rating. Silk Road stock will start trading Thursday.